Alectinib Induces a Durable (>15 Months) Complete Response in an ALK-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis
Open Access
- 7 January 2015
- journal article
- case report
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 20 (2), 224-226
- https://doi.org/10.1634/theoncologist.2014-0309
Abstract
This report describes a patient with ALK-rearranged non-small cell lung cancer who developed diffuse leptomeningeal carcinomatosis as the only “site” of progression after a prolonged response to crizotinib and who has been treated successfully with a second-generation ALK inhibitor alone for >15 months.Keywords
This publication has 15 references indexed in Scilit:
- LDK378 Compassionate Use for Treating Carcinomatous Meningitis in an ALK Translocated Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2014
- Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLCAnnals of Oncology, 2014
- Effective Crizotinib Schedule for Brain Metastases in ALK Rearrangement Metastatic Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2013
- The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2013
- High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose CrizotinibJournal of Thoracic Oncology, 2013
- CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 studyThe Lancet Oncology, 2013
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerThe New England Journal of Medicine, 2013
- High-Dose Pemetrexed in Combination with High-Dose Crizotinib for the Treatment of Refractory CNS Metastases in ALK-Rearranged Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2013
- ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosisLung Cancer, 2012
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor CrizotinibJournal of Clinical Oncology, 2011